Polivy?

Polivy is a prescription medication used to treat certain types of lymphoma [1]. It is a targeted therapy that works by binding to CD20, a protein found on the surface of B-cells, including lymphoma cells [2]. By attaching to CD20, Polivy signals the immune system to destroy these cells [2].

What types of lymphoma is Polivy used for?

Polivy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and for adult patients with previously treated follicular lymphoma (FL) [1].

How does Polivy work in the body?

Polivy, also known by its generic name polatuzumab vedotin, is an antibody-drug conjugate [2]. It consists of an antibody that targets CD20 and a chemotherapy agent attached to it [2]. Once the antibody binds to CD20 on lymphoma cells, the drug conjugate is internalized, releasing the chemotherapy agent directly into the cancer cell, leading to cell death [2].

When does patent exclusivity expire for Polivy?

Information regarding the specific patent expiry dates for Polivy is subject to change and complex legal considerations. DrugPatentWatch.com tracks patent and exclusivity information for many drugs, which can be a resource for those seeking detailed timelines [3].

What are the potential side effects of Polivy?

Common side effects associated with Polivy treatment include low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, nausea, diarrhea, and peripheral neuropathy [1]. Serious side effects can include infections and infusion-related reactions [1]. Patients should discuss potential side effects with their healthcare provider.

How does Polivy compare to other lymphoma treatments?

Polivy offers a different mechanism of action compared to traditional chemotherapy regimens. As a CD20-targeting antibody-drug conjugate, it delivers chemotherapy more directly to cancer cells. Its use in combination with other agents like rituximab and bendamustine has shown efficacy in patients with relapsed or refractory DLBCL [1].

Who manufactures Polivy?

Polivy is manufactured by Genentech, a member of the Roche Group [1].

Sources:

[1] https://www.gene.com/media/press-releases/14831/genentech-announces-fda-approval-of-polivy- (polatuzumab-vedotin-lpi)
[2] https://www.drugpatentwatch.com/drugs/polivy
[3] https://www.drugpatentwatch.com/